Overpriced drugs: SOMO and Wemos publication discussed in Dutch parliament
Recently, SOMO and Wemos published their research into the extent of Dutch public funding for drug development, through donations, loans and/or investments. The publication, Overpriced, reveals that because no conditions are set on these investments, the Government loses its chance to curb subsequent high drug prices. SOMO and Wemos argue the need for European legislation to ensure affordable medicines and a public return on public investment.
Overpriced drugs developed with tax money
Various national media outlets have covered the publication and Dutch politicians, Van Gerven (SP) and Ellemeet (GroenLinks), have used it to question the Minister for Medical Care and Sports, Bruno Bruins (VVD).
Want to know more? Read the full story here in Dutch.
Do you need more information?
-
Irene Schipper
Senior Researcher
Partners
Related news
-
EU health data law rolls out the red carpet for Big TechPosted in category:Long read
Irene SchipperPublished on: -
Civil society coalition urges EU to put the interests of patients and citizens at the heart of the European Health Data SpacePosted in category:Published on:Statement
-
